MetrioPharm Investor Relations News QI 2023

Invitation to a Webinar
"Host-mediated therapies for infectious diseases"

The iMPact project, funded by the European Union with MetrioPharm leading the consortium, will end in spring 2023. As part of the project, MetrioPharm's lead compound MP1032 has been evaluated both preclinically and clinically for its suitability to treat COVID-19. If you are interested in a detailed presentation and expert discussion on the results, we cordially invite you on behalf of the entire consortium:

An online webinar will take place on 19.04.23 from 15.00-17.00. During this webinar, we will present experimental studies on MP1032 in different virus variants and present a detailed insight into the clinical study and its results. In addition, experts will discuss how compounds like MP1032 can help protect patients and reduce the burden on healthcare systems during future pandemics.

This event will be held in English.
Kindly follow the link for free registration: https://bit.ly/3natHCR

MetrioPharm AG Company Calendar in H1 2023

  • 09-12th of January: JP Morgan Healthcare Conference, San Francisco, USA
  • 06-09th of February: BIO CEO & Investor Conference, New York City, USA
  • 01-02nd of March: 16th European Life Sciences CEO Forum (Sachs), Zurich, Switzerland
  • 20-22nd of March: BIO-Europe Spring, Basel, Switzerland
  • 28-29th of March: Deutsche Biotechnologietage, Wiesbaden, Germany
  • 24th of April: Swiss Biotech Day, Basel, Switzerland
  • 14-16th of May: Bio€quity, Dublin, Irland
  • 05-08th of June: BIO International Convention, Boston, USA

MetrioPharm AG informs

­ MetrioPharm uses various channels to inform its shareholders:
In addition to the quarterly newsletter, we also keep you informed about current events in the company with press releases. The press releases can also be found on our website here. If you have not yet been added to our distribution list for press releases, please send us an e-mail at invest@metriopharm.com and we will add you to the distribution list as soon as possible.

For background information on MetrioPharm, please visit our blog.

In November 2021, MetrioPharm signed a grant agreement from the European Commission for € 7.9 million. The project "iMPact" was among the 6 initiatives selected by the Commission to work on compounds for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19, as well as preclinical studies on the effect of MP1032 on mutant variants of SARS-CoV-2. More information on the iMPact project can be found here.

You can also network with MetrioPharm via LinkedIn. We use our LinkedIn profile to inform shareholders, experts and business partners about the latest company developments. Please feel free to include us in your LinkedIn community by invitation.


Your contact:

MetrioPharm AG Eva Brysch Investor Relations Managerin          

Lia Petridou
Corporate Communications & Press Relations

T +49 (0) 30 33 84 395 53
F +49 (0) 30 33 84 395 99
E press@metriopharm.com
W www.metriopharm.com



MetrioPharm AG Download PDF